Disease manifestation and disease management in chronic heart failure

Conditions

Chronic heart failure Circulatory System Heart failure

Judith Albert, Susanne Lezius, Stefan Störk, Caroline Morbach, Gülmisal Güder et al. (9 authors)

Journal of the American Heart Association2021-01-2626 citations

10.1161/jaha.120.017822

The omega-3 index in patients with heart failure: A prospective cohort study.

Berliner D, Mattern S, Wellige M, Malsch C, Güder G, Brenner S, Morbach C, Deubner N, Breunig M, Kiefl R, Angermann CE, Ertl G, von Schacky C, Störk S.

2018-11-2813 citations

10.1016/j.plefa.2018.11.012

Point-of-care B-type natriuretic peptide and portable echocardiography for assessment of patients with suspected heart failure in primary care: rationale and design of the three-part Handheld-BNP program and results of the training study.

Morbach C, Buck T, Rost C, Peter S, Günther S, Störk S, Prettin C, Erbel R, Ertl G, Angermann CE, Handheld-BNP Research Network.

2017-11-1513 citations

10.1007/s00392-017-1181-3

Prognostic significance of serial high-sensitivity troponin I measurements following acute cardiac decompensation-correlation with longer-term clinical outcomes and reverse remodelling.

Wallenborn J, Marx A, Störk S, Güder G, Brenner S, Ertl G, Angermann CE.

2017-01-058 citations

10.1016/j.ijcard.2017.01.021

A Functional Variant of The Neuropeptide S Receptor-1 Gene Modulates Clinical Outcomes and Healthcare Utilization in Patients with Systolic Heart Failure: Results from the Interdisciplinary Network Heart Failure (INH) Study

Christiane E. Angermann, Mathias Kaspar, Almuth Marx, Sarah Kittel‐Schneider, Dominik Menhofer et al. (10 authors)

European Journal of Heart Failure2016-12-1814 citations

10.1002/ejhf.706

Prognostic impact of subclinical thyroid dysfunction in heart failure.

Frey A, Kroiss M, Berliner D, Seifert M, Allolio B, Güder G, Ertl G, Angermann CE, Störk S, Fassnacht M.

2012-10-0249 citations

10.1016/j.ijcard.2012.09.064

Mode of action and effects of standardized collaborative disease management on mortality and morbidity in patients with systolic heart failure: the Interdisciplinary Network for Heart Failure (INH) study.

Angermann CE, Störk S, Gelbrich G, Faller H, Jahns R, Frantz S, Loeffler M, Ertl G, Competence Network Heart Failure.

2011-09-28182 citations

10.1161/circheartfailure.111.962969

Interventions

Current intervention as of 25/01/2021: The Interdisciplinary Network Heart Failure (INH) study was a two-arm parallel group randomised intervention study. Patients were randomised 1:1

however, quality of life improved and all-cause mortality risk was significantly reduced in the RPM group. The Extended (E)-INH study aimed to enroll a larger population to determine

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Age >18 years 2. Written informed consent 3. Heart failure documented by reduced left ventricular ejection fraction (<=40%) during hospitalisation and clinical signs/symptoms of heart failure (peripheral edema, pulmonary edema, rales, pulmonary congestion confirmed by X-ray, elevated jugular venous pressure, exertional dyspnea)

Exclusion criteria

Exclusion criteria: 1. Insufficient mental or verbal or physical ability to participate in a telephone assisted monitoring and education program 2. No telephone line installed

Design outcomes

Primary

Measure	Time frame
Current primary outcome measure as of 20/08/2009: 1. Death of any cause or hospitalisation of any cause (combined endpoint) Previous primary outcome measures: 1. Death of any cause or hospitalisation of any cause (combined endpoint) 2. Quality of life	—

Secondary

Measure	Time frame
Current secondary outcome measures as of 29/12/2020: 1. Components of composite primary endpoint 2. Quality of life 3. Cardiovascular death 4. Cardiovascular hospitalisation 5. Proportion of patients treated in adherence with current heart failure treatment guidelines 6. Cost-effectiveness analyses _____ Previous secondary outcome measures as of 20/08/2009: 1. Components of composite primary endpoint 2. Cardiovascular death 3. Cardiovascular hospitalisation 4. Proportion of patients treated in adherence with current heart failure treatment guidelines 2. Quality of life 5. Cost-effectiveness analyses _____ Previous secondary outcome measures: 1. Components of composite primary endpoint 2. Cardiovascular death 3. Cardiovascular hospitalisation 4. Proportion of patients treated in adherence with current heart failure treatment guidelines 5. Cost-effectiveness analyses	—

Measure

Time frame

Current secondary outcome measures as of 29/12/2020: 1. Components of composite primary endpoint 2. Quality of life 3. Cardiovascular death 4. Cardiovascular hospitalisation 5. Proportion of patients treated in adherence with current heart failure treatment guidelines 6. Cost-effectiveness analyses _____ Previous secondary outcome measures as of 20/08/2009: 1. Components of composite primary endpoint 2. Cardiovascular death 3. Cardiovascular hospitalisation 4. Proportion of patients treated in adherence with current heart failure treatment guidelines 2. Quality of life 5. Cost-effectiveness analyses _____ Previous secondary outcome measures: 1. Components of composite primary endpoint 2. Cardiovascular death 3. Cardiovascular hospitalisation 4. Proportion of patients treated in adherence with current heart failure treatment guidelines 5. Cost-effectiveness analyses

—

Countries

Germany

Outcome results

None listed